Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort.
Saeed A, Park R, Pathak H, Al-Bzour AN, Dai J, Phadnis M, Al-Rajabi R, Kasi A, Baranda J, Sun W, Williamson S, Chiu YC, Osmanbeyoglu HU, Madan R, Abushukair H, Mulvaney K, Godwin AK, Saeed A.
Saeed A, et al. Among authors: godwin ak.
Nat Commun. 2024 Feb 20;15(1):1533. doi: 10.1038/s41467-024-45960-2.
Nat Commun. 2024.
PMID: 38378868
Free PMC article.
Clinical Trial.